DEPO-TESTOSTERONE INJ 100MG/ML SOLUTION

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
12-07-2018

Virkt innihaldsefni:

TESTOSTERONE CYPIONATE

Fáanlegur frá:

PFIZER CANADA ULC

ATC númer:

G03BA03

INN (Alþjóðlegt nafn):

TESTOSTERONE

Skammtar:

100MG

Lyfjaform:

SOLUTION

Samsetning:

TESTOSTERONE CYPIONATE 100MG

Stjórnsýsluleið:

INTRAMUSCULAR

Einingar í pakka:

10ML

Gerð lyfseðils:

Schedule G (CDSA IV)

Lækningarsvæði:

ANDROGENS

Vörulýsing:

Active ingredient group (AIG) number: 0106401001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2001-06-04

Vara einkenni

                                _ _
_DEPO-TESTOSTERONE Product Monograph _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
DEPO-TESTOSTERONE
testosterone cypionate injection
100 mg/mL sterile solution
USP
Androgens
Pfizer Canada Inc.
17, 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
July 12, 2018
Submission Control No: 217239
©
Pfizer Canada Inc., 2018
_ _
_DEPO-TESTOSTERONE Product Monograph _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFO
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Vara einkenni Vara einkenni franska 12-07-2018

Leitaðu viðvaranir sem tengjast þessari vöru